Development asset linked to Formycon in public FDA and regional records.
pharma · NSCLC
Formycon
Formycon AG
Formycon drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Planegg, DE HQ
2012 Founded
178 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Planegg, DE
- Founded
- 2012
- Employees
- 178
- Programs
- 2
- Drugs
- 4
- Patents
- 0
Formycon pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Formycon drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Formycon in public FDA and regional records.
-
Development asset linked to Formycon in public FDA and regional records.